About Chugai
Chugai’s mission is
to create innovative drugs
for the benefit of patients.
News ReleasesRSS
- Jan 14, 2025 Transfer and Future Marketing of Anti-Cancer Agent “Tarceva® Tablets 25, 100 and 150” in Japan
- Jan 06, 2025 Introduction of a New Human Resources Management System
- Jan 06, 2025 Verastem Oncology’s Announcement Regarding Avutometinib (FDA Acceptance and Priority Review of New Drug Application for Avutometinib (in Combination with Defactinib) for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer)
- Dec 27, 2024 Chugai Obtains Regulatory Approval for “LUNSUMIO for Intravenous Infusion” for Relapsed or Refractory Follicular Lymphoma in Japan
- Dec 24, 2024 Chugai Received Second Rating in Pharmaceutical Sector in the “DJSI World,” a Global ESG Investment Index
